PDE5A and idiopathic pulmonary arterial hypertension: PDE5 inhibitors are important therapeutically in the treatment of primary pulmonary hypertension [138], although they have yet to be shown to have therapeutic value in patients with COPD who do not have primary pulmonary hypertension [139].